BRPI0519044B8 - anticorpo monoclonal direcionado contra o antígeno cd20 e seu uso - Google Patents

anticorpo monoclonal direcionado contra o antígeno cd20 e seu uso

Info

Publication number
BRPI0519044B8
BRPI0519044B8 BRPI0519044A BRPI0519044A BRPI0519044B8 BR PI0519044 B8 BRPI0519044 B8 BR PI0519044B8 BR PI0519044 A BRPI0519044 A BR PI0519044A BR PI0519044 A BRPI0519044 A BR PI0519044A BR PI0519044 B8 BRPI0519044 B8 BR PI0519044B8
Authority
BR
Brazil
Prior art keywords
directed against
antibody
antibody directed
antigen
monoclonal antibody
Prior art date
Application number
BRPI0519044A
Other languages
English (en)
Portuguese (pt)
Inventor
Gaucher Christine
De Romeuf Christophe
Prost Jean-François
Teillaud Jean-Luc
Original Assignee
Lab Francais Du Fractionnement
Lfb Biotechnologies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lab Francais Du Fractionnement, Lfb Biotechnologies filed Critical Lab Francais Du Fractionnement
Publication of BRPI0519044A2 publication Critical patent/BRPI0519044A2/pt
Publication of BRPI0519044B1 publication Critical patent/BRPI0519044B1/pt
Publication of BRPI0519044B8 publication Critical patent/BRPI0519044B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1069—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from blood cells, e.g. the cancer being a myeloma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BRPI0519044A 2004-12-15 2005-12-14 anticorpo monoclonal direcionado contra o antígeno cd20 e seu uso BRPI0519044B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0413320 2004-12-15
FR0413320A FR2879204B1 (fr) 2004-12-15 2004-12-15 Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b.
PCT/FR2005/003123 WO2006064121A2 (fr) 2004-12-15 2005-12-14 Anticorps cytotoxique dirige contre les proliferations hematopoïetiques lymphoïdes de type b

Publications (3)

Publication Number Publication Date
BRPI0519044A2 BRPI0519044A2 (pt) 2008-12-23
BRPI0519044B1 BRPI0519044B1 (pt) 2020-11-17
BRPI0519044B8 true BRPI0519044B8 (pt) 2021-05-25

Family

ID=34953790

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0519044A BRPI0519044B8 (pt) 2004-12-15 2005-12-14 anticorpo monoclonal direcionado contra o antígeno cd20 e seu uso

Country Status (16)

Country Link
US (2) US9234045B2 (enExample)
EP (2) EP1824887B1 (enExample)
JP (2) JP4999699B2 (enExample)
KR (3) KR101340192B1 (enExample)
CN (1) CN101115772B (enExample)
AU (1) AU2005315534B2 (enExample)
BE (1) BE2023C542I2 (enExample)
BR (1) BRPI0519044B8 (enExample)
CA (1) CA2590303C (enExample)
DK (1) DK1824887T3 (enExample)
ES (1) ES2588161T3 (enExample)
FR (2) FR2879204B1 (enExample)
IL (1) IL183947A0 (enExample)
NL (1) NL301242I2 (enExample)
PL (1) PL1824887T3 (enExample)
WO (1) WO2006064121A2 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
AU2005274905B2 (en) 2004-08-04 2010-12-23 Mentrik Biotech, Llc Variant Fc regions
FR2879204B1 (fr) * 2004-12-15 2007-02-16 Lab Francais Du Fractionnement Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b.
FR2879605B1 (fr) * 2004-12-16 2008-10-17 Centre Nat Rech Scient Cnrse Production de formats d'anticorps et applications immunologiques de ces formats
NZ589276A (en) 2005-02-03 2012-06-29 Topotarget Uk Ltd Combination therapies using hdac inhibitors and erlotinib (tarceva)
CA2606598C (en) 2005-05-13 2014-12-23 Topotarget Uk Limited Pharmaceutical formulations of hdac inhibitors
JP5740076B2 (ja) 2005-07-25 2015-06-24 エマージェント・プロダクト・ディベロップメント・シアトル・エルエルシー Ｃｄ３７特異的及びｃｄ２０特異的結合分子を用いたｂ細胞の減少
JP5377968B2 (ja) 2005-11-10 2013-12-25 トポターゲット ユーケー リミテッド 癌治療のために単独で用いるまたは化学療法薬と併用するヒストンデアセチラーゼ（ｈｄａｃ）阻害剤
US9382327B2 (en) * 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
FR2910896B1 (fr) * 2006-12-29 2012-11-16 Lab Francais Du Fractionnement Anticorps monoclonal dirige contre le recepteur humain des ldl
FR2915398B1 (fr) * 2007-04-25 2012-12-28 Lab Francais Du Fractionnement "ensemble de moyens pour le traitement d'une pathologie maligne, d'une maladie auto-immune ou d'une maladie infectieuse"
EP1985633A1 (en) * 2007-04-26 2008-10-29 LFB Biotechnologies Kit of parts for the treatment of cancer or infectious diseases
EP2203421B1 (en) 2007-09-25 2014-05-07 TopoTarget UK Limited Methods of synthesis of certain n-hydroxy-3-(3-phenylsulfamoyl-phenyl)-acrylamide compounds
CN105198997B (zh) 2008-04-11 2018-08-31 阿普拜佛研发有限责任公司 Cd37免疫治疗剂及其与双功能化学治疗剂的联合
TW201438738A (zh) 2008-09-16 2014-10-16 建南德克公司 治療進展型多發性硬化症之方法
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
FR2940616A1 (fr) * 2008-12-30 2010-07-02 Lfb Biotechnologies Utilisation d'un anticorps anti-cd20 pour le traitement du lymphome primaire intraoculaire.
EP2233500A1 (en) 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
US9173961B2 (en) 2010-02-10 2015-11-03 Immunogen, Inc. CD20 antibodies and uses thereof
FR2962908A1 (fr) * 2010-07-20 2012-01-27 Lfb Biotechnologies Formulation d'anticorps anti-cd20
FR2966043A1 (fr) * 2010-10-14 2012-04-20 Lfb Biotechnologies Utilisation d'un anticorps anti-cd20 pour le traitement du lymphome cerebral primitif
EP2647707B1 (en) 2010-11-30 2018-09-12 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
FR2976811A1 (fr) 2011-06-22 2012-12-28 Lfb Biotechnologies Utilisation d'un anticorps anti-cd20 a haute adcc pour le traitement de la maladie de waldenstrom
EP2537864B1 (en) 2011-06-24 2019-08-07 Laboratoire Français du Fractionnement et des Biotechnologies Fc variants with reduced effector functions
FR2980110A1 (fr) * 2011-09-20 2013-03-22 Lfb Biotechnologies Combinaison d'anticorps anti-cd20 et de bendamustine
US20150290244A1 (en) * 2012-07-13 2015-10-15 The Trustees Of The University Of Pennsylvania Use of cart19 to deplete normal b cells to induce tolerance
US9694071B2 (en) * 2012-11-02 2017-07-04 Tg Therapeutics, Inc. Combination of anti-CD20 antibody and PI3 kinase selective inhibitor
CN117535350A (zh) * 2016-05-20 2024-02-09 哈佛学院董事及会员团体 年龄相关疾病和病症的基因治疗方法
EA201892284A1 (ru) 2016-05-27 2019-08-30 Тг Терапьютикс, Инк. Комбинация антитела против cd20, селективного ингибитора pi3-киназы-дельта и ингибитора btk для лечения b-клеточных пролиферативных расстройств
JP2019526595A (ja) 2016-09-09 2019-09-19 ティージー セラピューティクス，インコーポレイテッド 血液癌を治療するための抗ｃｄ２０抗体、ｐｉ３キナーゼ−デルタ阻害剤および抗ｐｄ−１抗体または抗ｐｄ−ｌ１抗体の組み合わせ
WO2022104150A1 (en) 2020-11-12 2022-05-19 Tg Therapeutics, Inc. Triple combination to treat b-cell malignancies
US11814439B1 (en) 2022-06-01 2023-11-14 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11807689B1 (en) 2022-06-01 2023-11-07 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11965032B1 (en) 2022-06-01 2024-04-23 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11884740B1 (en) 2022-06-01 2024-01-30 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
WO2025199155A1 (en) * 2024-03-18 2025-09-25 Tg Therapeutics, Inc. Subcutaneous formulations of anti-cd20 antibody

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994011026A2 (en) * 1992-11-13 1994-05-26 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
WO1998041645A1 (en) * 1997-03-14 1998-09-24 Idec Pharmaceuticals Corporation Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
US8557244B1 (en) * 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
AU2002307037B2 (en) * 2001-04-02 2008-08-07 Biogen Idec Inc. Recombinant antibodies coexpressed with GnTIII
US7214660B2 (en) * 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
JPWO2003085107A1 (ja) * 2002-04-09 2005-08-11 協和醗酵工業株式会社 ゲノムが改変された細胞
FR2844513B1 (fr) * 2002-09-13 2007-08-03 Lab Francais Du Fractionnement Anticorps pour adcc et induisant la production de cytokines.
FR2844455B1 (fr) * 2002-09-13 2007-12-14 Lab Francais Du Fractionnement Traitement des pathologies echappant a la reponse immune par des anticorps optimises
US7595165B2 (en) * 2002-09-13 2009-09-29 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Method of measuring activation of effector cells
EA021644B1 (ru) 2002-10-17 2015-08-31 Генмаб А/С Человеческое моноклональное антитело против cd20 и его применение
PL212899B1 (pl) * 2002-12-16 2012-12-31 Genentech Inc Humanizowane przeciwcialo, kompozycja zawierajaca to przeciwcialo, wyrób fabryczny, przeciwcialo lub jego fragment do zastosowania w sposobie indukowania apoptozy, izolowany kwas nukleinowy, wektor ekspresji, komórka gospodarza, sposób wytwarzania przeciwciala lub jego fragmentu, plynny preparat i zastosowanie przeciwciala do wytwarzania leku
CN1542132A (zh) * 2003-04-30 2004-11-03 上海新霁生物科技有限公司 高效表达治疗肿瘤并含有人恒定区全抗体基因的重组病毒及其用途
WO2005063815A2 (en) * 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
FR2879204B1 (fr) * 2004-12-15 2007-02-16 Lab Francais Du Fractionnement Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b.

Also Published As

Publication number Publication date
BRPI0519044B1 (pt) 2020-11-17
AU2005315534B2 (en) 2011-11-10
DK1824887T3 (en) 2016-09-05
EP1824887B1 (fr) 2016-05-25
JP2012126724A (ja) 2012-07-05
JP4999699B2 (ja) 2012-08-15
CN101115772B (zh) 2012-10-17
KR101340192B1 (ko) 2013-12-12
FR2879204A1 (fr) 2006-06-16
ES2588161T3 (es) 2016-10-31
JP2008523793A (ja) 2008-07-10
KR20140003660A (ko) 2014-01-09
BRPI0519044A2 (pt) 2008-12-23
KR101418695B1 (ko) 2014-07-10
NL301242I1 (nl) 2023-09-20
BE2023C542I2 (enExample) 2025-02-07
FR2879204B1 (fr) 2007-02-16
FR23C1038I1 (fr) 2023-12-08
FR23C1038I2 (fr) 2024-05-03
JP5693440B2 (ja) 2015-04-01
US9234045B2 (en) 2016-01-12
AU2005315534A1 (en) 2006-06-22
US9873745B2 (en) 2018-01-23
EP1824887A2 (fr) 2007-08-29
US20090053233A1 (en) 2009-02-26
PL1824887T3 (pl) 2016-12-30
KR20120023177A (ko) 2012-03-12
WO2006064121A2 (fr) 2006-06-22
IL183947A0 (en) 2007-10-31
CA2590303A1 (fr) 2006-06-22
WO2006064121A3 (fr) 2006-08-31
CA2590303C (fr) 2015-05-26
EP2949674A1 (fr) 2015-12-02
US20160060350A1 (en) 2016-03-03
NL301242I2 (nl) 2023-11-01
CN101115772A (zh) 2008-01-30
KR20070102513A (ko) 2007-10-18

Similar Documents

Publication Publication Date Title
BRPI0519044B8 (pt) anticorpo monoclonal direcionado contra o antígeno cd20 e seu uso
BR112022009679A2 (pt) Receptores de antígeno quimérico cd19 e cd22 e usos dos mesmos
PH12020500078A1 (en) Anti-ctla-4 antibodies and uses thereof
AR071510A1 (es) Anticuerpos anti- factor d humanizados y sus usos
PH12015501763A1 (en) Humanized anti-factor d antibodies and uses thereof
CY1120018T1 (el) Θεραπεια του οικογενους μεσογειακου πυρετου με αντι-il-1b αντισωματα
CY1123534T1 (el) Αντισωματα που περιλαμβανουν τροποποιημενες βαριες σταθερες περιοχες
AR107902A2 (es) Anticuerpos anti-cd37
WO2010076400A8 (fr) Utilisation d'un anticorps anti-cd20 pour le traitement du lymphome intraoculaire primitif
BR112021024956A2 (pt) Anticorpos multiespecíficos de cadeia pesada que se ligam a cd22 e cd3
MA45976B1 (fr) Récepteurs de lymphocytes t et thérapie immunitaire les utilisant
MX2020001873A (es) Agentes de union.
BR112021025537A2 (pt) Azacitidina em combinação com venetoclax, gilteritinibe, midostaurina ou outros compostos para o tratamento de leucemia ou síndrome mielodisplásica
HK1254861A1 (zh) 抗lag3抗体及其用途
UA114879C2 (uk) Антитіло до cd38 для лікування раку
PE20200927A1 (es) Anticuerpos monoclonales que se unen a la region de la cadena beta de la familia trbv9 del receptor de las celulas t humanas
SA520420332B1 (ar) الأجسام المضادة لمكون مضاد للمتمم وطرق استخدامها
CO6180445A2 (es) Anticuerpos agonistas anti notch3 y su uso en el tratamiento de las enfermedades relacionadas con el gen notch3
HN2004000356A (es) Anticuerpos dirigidos a m-csf
BR112021009420A2 (pt) Métodos de dosagem de células t manipuladas para o tratamento de malignidades de células b
BR112022019060A2 (pt) Células neurais hipoimunogênicas para o tratamento de distúrbios e condições neurológicas
MX2022015769A (es) Tubulisinas y conjugados de proteina-tubulisina.
JOP20220117A1 (ar) مستقبلات المستضدات الخيمرية المضادة لـ cd79 وخلايا car التائية واستخداماتهما
MX2021012870A (es) Uso de un anticuerpo anti cúmulo de diferenciación 19 (cd19) para tratar enfermedades autoinmunitarias.
AR065818A1 (es) Metodos de tratamiento del cancer mediante administracion de combinaciones de il-18 humana

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: LFB BIOTECHNOLOGIES (FR)

Free format text: TRANSFERIDO DE: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOT

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 17/11/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/12/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25G Requested change of headquarter approved

Owner name: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES (FR)